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The development of new small molecule-based therapeutic drugs requires accurate quantification of drug bioavailability,
biological activity and treatment efficacy. Rapidly measuring these endpoints is often hampered by the lack of efficient
assay platforms with high sensitivity and specificity. Using an in vivo model system, we report a simple and sensitive liquid
chromatography-tandem mass spectrometry assay to quantify the bioavailability of a recently developed novel cyclindependent kinase inhibitor VMY-1-103, a purvalanol B-based analog whose biological activity is enhanced via dansylation.
We developed a rapid organic phase extraction technique and validated wide and functional VMY-1-103 distribution in
various mouse tissues, consistent with its enhanced potency previously observed in a variety of human cancer cell lines.
More importantly, in vivo MRI and single voxel proton MR-Spectroscopy further established that VMY-1‑103 inhibited
disease progression and affected key metabolites in a mouse model of hedgehog-driven medulloblastoma.

Introduction
The development of new small-molecule inhibitors for clinical
anticancer use has gained increased attention because of the central role that protein kinases play in cellular proliferation and cell
division. Many proteins have been identified as potential targets
of small-molecule inhibition to affect therapeutic intervention,
including the Rb/CDK4 complex, based on its central role in
cell cycle regulation,1 components of the PI3Kinase pathway,2 as
well as the heat shock protein HSP90 in melanoma 3 and Poly
(ADP-ribose) polymerase to sensitize brain tumors to radiation
treatment.4 However, establishing the bioavailability of new compounds can be confounded by a lack of rapid and robust assays.
For example, techniques such as radioimmunoassays, binding
assays5 and HPLC separation6,7 can frequently fail to meet the
requirements of throughput and accuracy, as they may lack sensitivity or specificity, may not be quantitative or may be time consuming. Similarly, documenting in vivo tumor responsiveness is
often very difficult due to, among other reasons, the anatomic

location of the tumor in organs such as the liver, prostate and
brain, and monitoring surrogate tissues such as peripheral blood
mononuclear cells does not always reflect antitumor activity.
The purvalanols are members of the 2,6,9-trisubstituted
purine group of cyclin-dependent kinase (CDK) inhibitors,
which are generally well tolerated in vivo.8 We have previously
established that VMY-1-103 (VMY), a dansylated analog of purvalanol B (PVB), induced apoptosis at least 10-fold more potently
in vitro than PVB in human prostate cancer,9 medulloblastoma
(MB)10 and breast cancer11 cell lines. Dansylation of compounds
is known for its ability to enhance detection by mass spectrometry,12 suggesting mass spectrometry could be used to evaluate
the distribution of VMY in both serum and tissue samples when
administered in vivo.
We have previously described the use of magnetic resonance
imaging (MRI) and the ND2-SmoA1 preclinical medulloblastoma (MB) mouse model for preclinical testing of small-molecule compounds for the treatment of MB,13 and we have used
anatomical MRI and proton MR-spectroscopy (1H-MRS) to
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follow tumorigenesis in mouse models of prostate,14 breast15 and
gastric16 cancers. In the present study, we evaluated VMY’s bioavailability and efficacy in normal and ND2-SmoA1 mice using
LC-MS/MS and MRI.
Herein, we provide the methodologies necessary to perform
rapid tissue extraction of VMY and PVB using a phase separation
technique and coupled this to detection by liquid chromatography tandem mass spectrometry (LC-MS/MS). Through applying area under the curve (AUC) analyses, quantification of VMY
in target tissues, such as brain, prostate, blood and urine, was also
achieved. In addition, longitudinal MRI and single voxel proton
MR-spectroscopy (1H-MRS) enabled an in vivo visualization of
VMY’s impact on MB, establishing that VMY was able to affect
changes in tumor metabolism and block disease progression in
the ND2-SmoA1 medulloblastoma model.
Results
To establish the use of LC-MS/MS as a quantitative method
for measuring these compounds, direct injections of VMY and
PVB were performed in the positive mode and yielded a base
peak of 433.2 m/z (M+1) for PVB, as predicted by the molecular mass (Fig. 1A), and a base peak at 708.3 m/z (M+1) for

3802

Cell Cycle

Volume 11 Issue 20

©2012 Landes Bioscience. Do not distribute.

Figure 1. Detection of (A) PVB (433.2 m/z, 7.7 min) and (B) VMY (708.3
m/z, 8.7 min) by LC-MS/MS in the positive mode.

VMY, as predicted (Fig. 1B). The peak intensities of PVB and
VMY occurred at 7.7 and 8.7 min, respectively. Standard curves
for VMY and PVB were run on serial dilutions in methanol as
described in the Methods (Fig. 2). Each standard curve was run
in triplicate. Both calibration curves showed high linearity with
VMY having a linear range of 0.00018–14.0 μM and PVB having a linear range of 0.0024–2.0 μM with R-squared values of
0.997 and 0.995, respectively.
The lowest limit of quantitation (LLOQ) was defined as
the lowest concentration at which the MS signal was equal to
20 kilocounts, or the signal to noise ratio was greater than 10.
Using these values and the data from the calibration curves the
calculated LLOQ values for VMY and PVB were projected to be
0.15 nM and 2.2 nM, respectively.
We next determined the empirical limit of detection. Limiting
dilutions of PVB and VMY were performed to define the limits of
detection for both compounds, and area under the curve analyses (AUC) were performed to quantify the sample. The observed
LLOQ values of VMY and purvalanol B were 0.18 nM for VMY
and 2.4 nM for PVB (Fig. 3) and were in agreement with the projected values of 0.15 nM for VMY and 2.2 nM for PVB. These
experiments establish that dansylation both increased measurement sensitivity by approximately 15-fold at the lowest limits of
detection and significantly increased the linear range of VMY
quantification.
Effects of danyslation on solubility. Having developed an
accurate and sensitive assay for VMY and PVB, we next addressed
the effects that danyslation may have on the chemical characteristics of VMY. We previously established that VMY was significantly more effective than PVB in inducing cell cycle arrest and
apoptosis in cancer cells9-11 and hypothesized that the dansyl modification increased the VMYs lipophilicity, enhancing its ability to
traverse the cell membrane. In order to quantify the lipid solubility of both VMY and PVB, we performed partition coefficient
measurements, which quantifiy solubility in either an organic or
aqueous phase. Using phosphate buffered saline and n-octanol
and applying the LogD formula described in the Methods section, the partition coefficients of VMY and PVB at pH 7.4 were
found to be 2.03 ± 0.02 (n = 3) and 0.15 ± 0.002 (n = 3), respectively, confirming the increased lipophilicity of VMY.
LC-MS/MS detection of VMY in mouse tissue. In order
to perform calculations of the concentration of VMY or PVB
contained within tissue fragments, the methodology for, and
efficiency of, extraction of VMY and PVB from tissue was first
established. Efficiencies of extraction were modeled by injecting
1.55 micromoles in 55 microliters of either compound into 108 μg
fragments of fresh mouse spleen. The tissues were stored on ice
for 60 min. The fragments were homogenization in water, and
an organic phase extraction methodology using dichloromethane (DCM) was developed as described in the Methods section.
Following the organic phase extraction and separation by centrifugation, the samples were lyophilized, resuspended in methanol
and quantified by LC-MS/MS as described in the Methods section. Using this method, both compounds were equally recovered
from tissue at an average of 97% efficiency (n = 3, not shown),
establishing that the different LogD values for VMY and PVB

do not adversely influence recovery of the compounds from tissue
using the methods we developed.
For in vivo delivery experiments, mice were injected with
either vehicle (peanut oil), VMY or PVB at 20 mg/kg. Tissues
were collected at 1, 4 and 24 h after injection. Venous blood was
collected from the heart. The excised tissues were weighed on
an analytical balance, homogenized in water and processed as
described in the Methods section. As an internal standard, 125
nanomoles of PVB was added to the VMY samples, followed
by LC-MS/MS as described. Chromatograms from representative kidney samples are shown (Fig. 4A). The peak intensities
occurred at 7.7 min for the PVB internal standard and 8.7 min
for VMY, as expected. The kinetics and distribution of VMY in
tissue are shown (Fig. 5). At 1 h post injection, VMY was easily
detected in prostate, pancreas, fat, urine, serum and spleen. By
4 h, VMY was detected at its highest levels in these tissues and
was also found in the kidney (Fig. 5A). At the 24 h time point,
VMY was detectable in all tissues, except the spleen, at reduced
levels vs. the 4 h time point (Fig. 5A). VMY was also administered at 20 mg/kg by oral gavage, and the highest amount of
VMY was found in the kidney and serum at 1 h, and in the pancreas and spleen at 4 h, post-injection (Fig. S1A).
We next investigated the tissue distribution of PVB similarly
administered at 20 mg/kg via intraperitoneal injection. PVB was
detected in kidney, spleen, pancreas, prostate lung and serum
(Fig. 5B). The overall tissue and serum levels of PVB, while lower
than VMY (note differences in scale), were generally within the
linear range of detection.
LC-MS/MS detection of VMY in brain tissue. Tissue samples from the normal cerebellum and cortex were excised from
mice 4 hours after VMY injection. As with the other tissue
samples, the brain samples were homogenized in water, extracted
with DCM and analyzed by LC-MS/MS. While measurable
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amounts of PVB were not detected in the cortex or cerebellum
(Fig. 5C), VMY at concentrations of 0.14 ± 0.05 uM and 0.53 ±
0.17 uM were found in the cerebellar and cortical tissue, respectively (Fig. 5C). Similar results were seen for VMY delivery to
the brain following oral gavage (Fig. S1B).
We have previously used the the ND2-SmoA1 mouse model
of human medulloblastoma (MB) to establish that subclinical
doses of the FDA-approved antineoplastic compound arsenic trioxide were effective at treating MB in vivo.13 Since VMY was
present in the brain of normal mice with intact blood brain barriers (BBB), we investigated whether VMY could be found in the
tumors of MB-bearing mice, which have a compromised BBB.
ND2-SmoA1 mice with spontaneous tumors were identified by
MRI, as previously described,13 and the mice were treated with
VMY as above. MB samples collected 4 hours after injection had
an average VMY concentration of 0.5 ± 0.2 uM (Fig. 5C).
VMY decreases tumor growth and metabolism in the
SmoA1 mouse model of MB. Since VMY was readily detectable
in MB tumors, we performed longitudinal studies investigating
the effect of VMY on tumor growth. Once tumors were detected
by MRI, initial tumor volumes were established by manual segmentation. Animals were randomly chosen for intraperitoneal
injections with either VMY (20 mg/kg as above) or vehicle (peanut oil), and the treatments performed three times per week for
up to 12 weeks as an endpoint. There were no significant differences in tumor volume at initial diagnosis, (p = 0.20 using a
one-tailed Mann-Whitney U test, n = 6, Fig. 6A), and no significant toxicities were observed during the study. Final tumor
volumes were established by MRI followed by termination of the
study. The average tumor volume as established by manual segmentation was 1.46 ± 1.21 mm3 for control and 0.31 ± 0.25 mm3
for VMY, which is statistically significant (p = 0.03, n = 6 mice
in each group) using a one-tailed Mann-Whitney U test. The
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Figure 2. Calibration curves. (A) LC-MS/MS calibration curves of PVB (7.7 min) and VMY (8.7 min) at the concentrations shown. (B) Calibration curve
calculations and R correlation coefficients for VMY and PVB.

Figure 3. Limits of detection by LC-MS/MS. VMY and PVB at the concentrations shown and plotted against count intensities in arbitrary units
(AU). Data are average ± standard deviation of n = 3 separate experiments. *, p < 0.01 vs. PVB using Student’s t-test’s

overall fold-increase in tumor volume from initial diagnosis to
study termination was found to be 10.0 ± 3.6 (SEM)-fold in control animals vs. 3.74 ± 1.45 (SEM)-fold in VMY-treated animals,
a statistically significant difference (p = 0.014, n = 6). Single voxel
proton MR-spectroscopy (1H-MRS) was used to interrogate tissue metabolism, as described in the Methods and in previous publications.14,15 A representative example of voxel placement and the
resulting 1H-MR spectra is shown (Fig. 6B). The relative ratios
of tumor metabolites relative to levels of total creatine (Cr) were
derived following approximately 2 weeks of treatment. Creatine
levels are relatively constant even under certain pathological
conditions, and this marker is commonly utilized as an internal
1
H-MRS reference. The 1H-MRS revealed that VMY treatment
resulted in statistically significant increases in the ratios of Tau
(taurine, p = 0.024, n = 3) to Cr and mI (myo-inositol, p = 0.024,
n = 3) to Cr, using one-tailed Mann-Whitney U tests, with little
to no changes in the Cho (choline) or NAA (N-acetyl-aspartate)
to Cr ratios (Fig. 6C). Following termination of the study, histological and immunohistochemical analyses revealed an overall
change in tumor architecture by VMY, including extensive areas
containing cells with condensed or fragmented nuclei indicating
cellular necrosis (Fig. S2). Using one-tailed Mann-Whitney U
tests, VMY was found to induce significant increases in TUNELpositive cells (8.9% ± 1.8 for VMY vs. 5.9% ± 0.5 for control,
p = 0.01, Fig. 6D) and PCNA-positive cells (38.3% ± 12.4 for
VMY vs. 13.3% ± 12.1 for control, p = 0.025, Fig. 6D), with
concomitant decreases in nuclear cyclin D1 positivity (13.8% ±
4.0 for VMY vs. 33.1% ± 4.9 for control, p = 0.024, Fig. 6D).
These data are consistent with VMY-induced apoptosis and cell
cycle arrest in G2 /M17 and consistent with VMY’s effects on cell
cycle progression and apoptosis in human medulloblastoma cell
lines in vitro.10

3804

The ability to rapidly and accurately quantify the delivery of
therapeutic compounds to target tissues is an important component of drug discovery as well as the preclinical testing of novel
agents. Unfortunately, the assays used to perform these analyses
are often complicated, time consuming and, in some cases, indirect. In the present study, we established a simplified methodology to quantify, VMY and PVB, members of the trisubstituted
purine analog family of small-molecule inhibitors, from mouse
serum. While we have shown that dansylation allows for the in
vitro identification by fluorescence microscopy of prostate and
medulloblastoma cells that contain VMY,9,10 this fluorophore
was insufficient for imaging or quantification of drug delivery
in vivo (not shown). However, since dansylated compounds are
readily detectable using mass spectrometry, our expectation was
that VMY’s dansyl group would enhance our ability to measure
tissue distribution by LC-MS/MS. VMY’s detection sensitivity
was increased by nearly 15-fold at the lowest limits of detection,
and overall sensitivity increased approximately 2-fold vs. PVB.
As shown in Figure 2, PVB and VMY have different column retention times. We took advantage of this chemical difference to overcome the need for performing total ion counts for
quantification of VMY. By using multiple ion trapping, we were
able to detect PVB and VMY individually in separate channels,
allowing the use of PVB as an internal standard for VMY tissue quantification. One of the major challenges was developing
a method to extract the small-molecule inhibitors from various
tissues, including the blood, without significant sample loss or
residual tissue fragmentation that could compromise the ability
to perform spectrometry. We found that an aqueous tissue sonification followed by dichloromethane extraction and phase separation centrifugation, a procedure we developed, was superior
to other methods, such as methanol and acetonitrile extraction
and syringe-driven filtration (not shown). The dichloromethane
extraction and centrifugation effectively forced hydrophilic cellular components, including tissue fragments, into the aqueous
layer, while the hydrophobic VMY and PVB compounds were
retained in the organic layer, allowing for quick and accurate collection without the need for filtering. In addition, neither VMY
nor PVB were detected in the aqueous layer (Fig. S3), indicating that dichloromethane is an appropriate solvent, and extraction conditions provided for extremely efficient recovery of this
class of compound. Although dichloromethane can be injected
directly into the ESI ion trap, we found that evaporation of the
DCM and resuspension in methanol yielded excellent reproducibility, possibly due to better ionization by methanol (not shown).
We had previously speculated that VMY’s increased potency
might be due in part to increased lipid partitioning provided by
the dansyl group, allowing for better transport across the cell
membrane.9-11 We now show that VMY is significantly more lipid
soluble than PVB and, consistent with this, we found VMY at
higher overall amounts in the blood and tissues, such as prostate,
which is one of the proposed target organs for VMY therapy.
In addition, while VMY was consistently found in MB tumor
samples, as anticipated, VMY was also present in the brain
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Figure 4. Measuring VMY or PVB in tissue samples. Representative dual
ion LC-MS/MS tissue spectra from mice injected with (A) VMY, (B) PVB
and (C) vehicle (peanut oil).

new and existing drugs. Importantly, all of the methodological
approaches we have described can be easily translated into clinical use, furthering our ability to predict tumor responsiveness in
vivo and to accurately measure drug delivery and efficacy using
biopsied tissue.
Methods and Materials
Chemicals. Purvalanol B (P5234) and Octanol (112615) were
purchased from Sigma-Aldrich. HPLC grade methanol, HPLC
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samples of normal mice with intact BBBs. One of the challenges
for developing drugs that are meant to target brain malignancies
is documenting their ability to cross the BBB. Methodologies for
delivering drugs to the brain have involved intrathecal administration, convection enhanced delivery via surgically implanted
catheters, intra-arterial delivery, surgical implantation with drug
impregnated discs as well as BBB disruptants such as bradykinin,
mannitol or high intensity focused ultrasound.18-20 More recently
the BBB has been evaded by activating adenosine receptors,21 further underscoring the need for compounds that contain an inherent ability to cross the BBB. Our data establish that delivery of
purvalanol-based compounds across an intact BBB can be effectuated via dansylation, raising the possibility that similar modifications of other compounds may enhance the rational design of
brain targeted therapeutics delivered intravenously, orally or via
other routes, such as intranasal administration. Moreover, dansylation also served as an effective “tag,” greatly increasing the
measurement of drug via a rapid and sensitive mass spectrometry-based detection method. Such an approach could be useful in future studies, whereby biodistribution and detection are
enhanced simultaneously with a single modification.
Finally, we have applied MRI and 1H-MRS to non-invasively
measure tumor responses to VMY. In addition to inhibiting
tumor growth as measured by segmentation, 1H-MRS established
that the relative concentrations of taurine and myo-inositol were
altered in tumors following treatment with VMY. Taurine has
been found to play a variety of possible roles in the nervous system,
including affecting osmoregulation, maintaining the integrity of
the membrane, regulating calcium transport and homeostasis
and, possibly, functioning as a neuroprotectant.22 The increase in
Tau seen following VMY treatment may be related to its osmogregulatory role, or perhaps it is in response to the increase in
overall cellular apoptosis brought about by VMY. Myo-inositol
is considered a marker of glial cells and changes in the levels of
mI are associated with white matter diseases and grade II astrocytomas.23 Additionally, mI is expected to be altered in response
to damaged cellular membranes, and increased mI levels are also
associated with inflammation, and the histological data from the
mice confirms an increase in inflammation. Other key metabolites were not significantly affected. Choline levels are abundant
in the MBs of this mouse model,24 and studies have established
that the levels of choline levels are relatively consistent both in
brain tumors and in normal brain tissue,25-27 and our data support
these finding. N-acetylaspartate (NAA) is a marker of neuronal
metabolism and the relative levels of NAA were unaffected by
VMY treatment, suggesting that VMY did not have an overall
adverse effect on the brain, as levels of NAA would be expected
to change. Based on these data we believe that 1H-MRS may be
a more sensitive and therefore a more effective early measure of
drug effectiveness than are changes in overall tumor volume, and
additional studies are underway to explore this hypothesis.
The development of non-invasive imaging methods to measure responses to chemotherapy, combined with post-mortem
data including drug bioavailability, histopathology and molecular analyses, performed in biologically relevant preclinical models will enhance our ability to investigate the applicability of

Table 1. Liquid chromatography tandem mass spectrometry
Mass spectrometer parameter

Figure 5. In vivo tissue delivery and quantification. Tissue samples
were collected at the times shown from mice that received intraperitoneal injections of (A) 20 mg/kg VMY or (B) 20 mg/kg PVB (note: Y
axis is micromolar in (A) vs. nanomolar in (B). (C) Brain tissue from mice
injected with VMY or PVB. All data are average ± standard deviation of
three separate samples. Panc, pancreas; Cb, cerebellum; Ctx, cortex;
MB, medulloblastoma; N.D., not determinable (below levels of detection).

grade dichloromethane (DCM), HPLC grade water, phosphate
buffered saline (PBS) pH 7.4 and formic acid were purchased
from Fisher Scientific.
VMY-1-103 synthesis and purification. VMY-1-103 was synthesized as previously described. Briefly, starting from commercially available 2-fluoro-6-chloropurine, standard N-9 alkylation
with 2-propanol under Mitsunobu conditions gave 2-fluoro6-chloro-9H-isopropylpurine. The 6-position was substituted
with dansyl ethylenediamine, followed by substitution at the
2-position (R)-valinol, yielding VMY-1-103.11

3806

50°C
Nitrogen
35 p.s.i.
350°C
18 p.s.i.
5000 V
600 V
0.30 Hz

SmoA1-ND2 preclinical mouse model. We have recently
described the use of the ND2-SmoA1 preclinical medulloblastoma (MB) mouse model (a generous gift from James Olsen) for
preclinical testing of small molecule compounds for treatment
of MB.13 Briefly, this model contains the SmoA1 constitutively
active point mutation of the Smoothened transmembrane receptor under the control of the NeuroD2 mouse promoter, resulting in spontaneous cerebellar medulluloblastoma at 3–4 mo of
age. Normal, nontransgenic C57Bl6 mice were also used for
in vivo drug studies. All mice were kept, handled and euthanized in accordance with the Georgetown University Division
of Comparative Medicine’s ethics guidelines and conditions.
Mice were genotyped for the SmoA1 transgene as previously
described.13 VMY or PVB were solubilized in peanut oil and were
administered at 20 mg/kg. For timepoint studies, mice were sacrificed 1 h, 4 h and 24 h after injection. Serum and tissue were
collected at necropsy. Mice with medulloblastoma were identified
by MRI as previously reported13 and described below.
MRI. All MRI procedures were performed on the 20 cm bore,
7T Bruker horizontal magnet running Paravision 5 (Bruker)
in the Georgetown-Lombardi Preclinical Research Imaging
Laboratory. Quantitative tumor volumetric analyses were performed essentially as previously described.28 Mice were anesthetized using 1.5% isoflurane and 30% nitrous oxide and positioned
inside the magnet using a custom-designed animal management
system with temperature and respiration control,28 which was
with further adapted to accept a Bruker 4 channel brain array
coil. The imaging protocol used for anatomical evaluation was a
T2-weighted RARE (rapid acquisition with relaxation enhancement) with the following parameters: matrix: 256 × 256, TR:
4660 ms, TE: 36 ms, spatial resolution: 137 μm/pixel and slice
thickness: 0.5 mm. Quantitative tumor volumetric analyses were
performed as previously described.14
MRS. Single voxel proton MRS was performed using PRESS
(Position Resolved Spectroscopy Sequence), essentially as previously described.14,15 Briefly, parameters of the MRS sequence
are: TE: 20 ms, TR: 2500 ms, averages: 1,024, spectral width of
4 kHz, and 2,048 complex data points and 6 Hz line broadening, using a voxel of 1–2 mm on edge located entirely in tumor
areas avoiding contamination from normal brain tissue. The
voxel was positioned using the RARE anatomical image as a
locator scan. Quantification of neurochemicals was performed
using the Bruker software program TOPSPIN. When necessary,
corrections were made for voxel volume related to the size, shape
and location of the tumor. For comparison of in vivo MRS data,
creatine was used as the internal standard. Statistical analyses
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Spray chamber temperature
Nebulizer gas
Nebulizer pressure
Drying gas temperature
Drying gas pressure
Needle voltage (+)
Sprayshield voltage (+)
Data rate

were performed using the Mann-Whitney U test due to the
small sample size, and actual p values are shown. Tissue and
serum samples were harvested at the termination of the study
and either immediately fixed in formalin or processed for mass
spectrometry.
LC-MS/MS detection of compounds. Mass spectrometry.
Varian workstation software version 6.9.1 was used operate
the LC-mass spectrometer and autosampler. Drug detection
and quantification was performed using a Varian 500 ion trap
LC-MS/MS. Ionization was done using electrospray interface
(ESI) in the positive mode with operating conditions summarized in Table 1. VMY (exact mass 707.28 amu) was detected
as an (M+1) ion at 708.35 m/z. PVB (exact mass 432.17) was
detected as an (M+1) ion at 433.21m/z. Conditions for detection
of VMY and PVB are summarized in Table 2. Both VMY and
PVB were detected simultaneously in a single run using two different channels.
Liquid chromatography. Varian 212-LC chromatography
pumps were used with a Pursuit XRs 3 μm C18 100X2.0mm
column, Restek Ultra 5 μm 20X2.1 mm guard cartridge. Water
with 0.1% formic acid and methanol with 0.1% formic acid were
passed through though pumps A and B, respectively. The pump
program is summarized in Table 3. Columns were equilibrated
for 15 min between automated runs with 7 min for ramp and 8
min for hold which was found to be optimum for this system.

www.landesbioscience.com

Autosampler. A Varian Prostar 410 autosampler was used for
automation purposes. 10–20 μL injections were done using partial loop fill technique for maximum reproducibility.
Sample preparation. Fresh tissue samples were resuspended
in 80 μL of methanol and transferred to 0.25 mL glass conical
inserts with poly-support springs (VWR 46610–762) inside of
Snap-vials (National Scientific) and injected using partial-loop
uL injection. Standard curves were generated using serial dilutions of stock VMY and PVB made in methanol at concentrations
of 4, 2, 1, 0.5, 0.25, 0.02 μM, and analyzed by LC-MS/MS using
the described method above. The R-values for VMY and PVB
were calculated using GraphPad Prism software by plotting the
linear regression against the calibration curve intensity values.
Statistical and empirical limit of quantitation (LOQ ). Ten blank
controls with a matrix identical to the experimental samples were
analyzed by LC-MS/MS, and the mean blank signal value and
SD were calculated. The statistical LOQ (SA)LOQ was calculated
from the mean blank value plus 10 standard deviations and summarized in the equation below, where (SA)LOQ is the signal at the
limit of quantitation, (Sreag) is the value of the average blank signal, σ is the standard deviation, and z is the significance level (set
to 10 for the strictest criteria). The lowest limit of quantitation
(LLOQ) is the lowest concentration in the calibration curve at
which the (SA)LOQ signal was equal to 20 kilocounts or the signal
to noise ratio greater than 10. (SA)LOQ = Sreag + zσreag.
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Figure 6. Effect of VMY on tumor growth and metabolism. (A) Initial and final tumor volumes as measured by MRI. Data are average ± of either standard deviation (SD) or standard error of the mean (SEM) of n = 6 mice in each group. (B) Representative voxel placement and in vivo MR-spectral profile
of MB. (C) Effect of VMY on metabolite ratios. Metabolite ratios were established relative to creatine (Cr). (D) TUNEL, PCNA and cyclin D1 immunohistochemical staining of control and VMY-treated MB samples from the mice in (A–C). Abbreviations: mm3, cubic millimeters; Cre, creatine; Tau, taurine;
NAA, N-acetyl-apartate; PPM, parts per million. Data are average ± standard deviation of n = 3 mice asterisk, p < 0.05 using one-tailed Mann Whitney
U-tests.
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Table 3. Pump program
Time (min)

%A

%B

Flow rate µl/min

Pressure (psi)

0:00
10:00
15:00

50
0.0
0.0

50
100
100

200
200
200

2340
1020

Quantification of VMY and PVB. The quantification of
VMY and PVB in tissue was performed by using Area Under
the Curve analysis (AUC) by integrating the peak intensity curve
derived from LC-MS/MS using MS Data Viewer 6.9.1 software
(Varian, Inc.). For tissue delivery analyses, each VMY sample was
normalized using the internal standard and the total quantity of
VMY was calculated by comparing the AUC of each normalized
sample to the VMY calibration curve. Statistical significances
calculations were performed using Student’s t-tests
Isolation of VMY and PVB from tissue by phase separation. VMY or PVB was isolated from tissues using the following method. Mouse tissues, removed of any adherent liquid or
moisture, were weighed on an analytical balance and individually placed in 2.0 mL Eppendorf tubes. 600 μL of HPLC grade
distilled deionized H2O was added, and the tissues were homogenized on ice using an OMNI Tissue Homogenizer (TH-115)
equipped with two-piece OmniTip (3750H) at 35,000 rpm
in three 45 sec bursts, incubating the sample on ice for 2 min
between each burst. Next, 600 μL of HPLC grade dichloromethane (DCM, Fisher Scientific) was added to the homogenized
sample, and the tube was vortexed for 1 minute and incubated
on ice for 2 h. The sample was centrifuged at 14,000 rpm using
an Eppendorf 5415R refrigerated centrifuge at 4°C for 20 min,
resulting in a biphasic solution comprised of an aqueous layer
with tissues debris and a clear DCM layer. The organic layer containing the VMY or PVB and the aqueous phases were collected
separately in fresh tubes. This extraction process was repeated
twice by adding an additional 600 μL of DCM to the original
dH20 and tissue and re-extracting to obtain the maximum recovery. The DCM and aqueous layers from all three extractions were
lyophilized to dryness and stored at -20°C. A modified procedure was performed to isolate VMY or PVB from the circulation,
in which 30 μL of serum was aliquoted into 600 μL of HPLC
grade dH20, and the DCM extraction procedure was performed
without sonication. To validate that DCM extraction effectively
extracted VMY and PVB from the tissue and aqueous phase, the
aqueous fraction was subjected to LC-MS/MS and neither VMY
nor PVB was found (Fig. S3).
For quantification of VMY across multiple experiments, 125
nanomoles of PVB was added as an internal standard to each
sample prior to LC-MS/MS analysis.
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Octanol-PBS partition coefficient (logD). The octanol
and phosphate-buffered saline (PBS, pH 7.4) partition coefficient (logD) was determined using the traditional shake flask
method29,30 at 37°C. In a 4 mL vial, 1 mg of each test compound
was weighed and dissolved in 1 mL of octanol-pre-saturated
PBS, which was then shaken with 1 mL of PBS-pre-saturated
octanol for 24 h at 37°C. The velocity of shaking was carefully
chosen to prevent emulsion formation while allowing thorough
mixing. After 24 h, the two phases were separated by centrifuging at 10,000 rpm for 10 min, and each layer was transferred
into separate vials. The individual samples were injected into an
LC-MS/MS to detect the quantity of the specified compound
in each layer. The peak intensity value was used to calculate the
area under the curve (AUC). The partition coefficients at pH
7.4 (LogD7.4) of VMY and PVB were calculated using the AUC
of the peak intensity and employing the equation: LogD7.4 =
Log10(AUCoct/injection volume of octanol phase) /(AUCbuffer/
injection volume of buffer phase).
Immunohistochemical staining. Immunohistochemical
staining was performed on prostate tissue as previously
described.13,31-34 The slides were blocked for 20 min and incubated overnight at 4°C with the primary antibody. Detection
was performed as previously described.13,31-34 Because of the small
sample size statistical analyses were performed using the MannWhitney U test and actual p values are shown.
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